Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

The vaccine will be Moderna’s second product to enter the U.S. market after the FDA’s approval of the biotech company’s COVID ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 ...

Moderna said the Spikevax 2024-2025 formula is expected to be available across the U.S. in the days immediately following approval. Pfizer also said shipping will begin immediately. Thursday ...

Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus. The company also has a combination flu/COVID vaccine and an ...

Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...

On the heels of the nation’s biggest summer COVID surge—test positivity peaked at 17.8% the week ended Aug. 10—help has arrived. The 2024–25 coronavirus vaccines, initially anticipated ...

Moderna laid out three priorities at its Investor Day. The first was to increase the usage of its Spikevax and mRESVIA vaccines. Spikevax is the company's current COVID vaccine, which was recently ...